Wednesday, May 23, 2012
Halo Therapeutics LLC, of Newton, Mass., received funding of $1.1 million from 12 nonprofit foundations dedicated to muscular dystrophy. Halo will use the funding to support its Phase II trial of HT-100 for Duchenne's muscular dystrophy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.